Immunogenic cell death: A link between gut microbiota and anticancer effects.

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• Intratumor bacterial injection shows anticancer potential, but often uses pathogenic strains.
• The gut microbiota significantly impacts immunotherapy and immune responses.
• Accumulating evidence highlights the role of immunogenic cell death (ICD) in various cancer therapies.

Purpose of the Study:

• To explore the potential mechanism linking gut microbiota and the anticancer efficacy of immune-based drugs.
• To investigate how gut microbiota influences the immunogenic cell death (ICD) pathway.
• To highlight ICD as a potential key mediator between gut microbiota and cancer treatment outcomes.

Main Methods:

• Literature review of studies on gut microbiota, immunotherapy, and cancer.
• Analysis of existing research on immunogenic cell death (ICD) mechanisms.
• Synthesis of evidence to propose a mechanistic link between gut microbiota and ICD.

Main Results:

• Gut microbiota plays a critical role in modulating immune responses relevant to cancer.
• Immunogenic cell death (ICD) is crucial for the efficacy of multiple cancer treatment modalities.
• The gut microbiota may significantly impact the induction and effectiveness of ICD.

Conclusions:

• Gut microbiota composition can influence patient response to cancer immunotherapy.
• Immunogenic cell death (ICD) is proposed as a central mechanism connecting gut microbiota and anticancer drug efficacy.
• Further research is needed to elucidate the precise mechanisms by which gut microbiota affects ICD pathways.